Lenvatinib exposure induces hepatotoxicity in zebrafish via inhibiting Wnt signaling

Ling Huang1, Jieping Liu1, Wanbo Li1

  • 1Key Laboratory of Healthy Mariculture for the East China Sea, Ministry of Agriculture and Rural Affairs, Jimei University, Xiamen, China.

Toxicology
|September 17, 2021
PubMed

Insights

Lenvatinib (cancer drug) causes developmental defects and liver toxicity in zebrafish embryos by disrupting Wnt signaling and increasing oxidative stress. Astaxanthin and Wnt activation offer partial protection.

Area of Science:

  • Developmental Toxicology
  • Pharmacology
  • Zebrafish Models

Background:

  • Lenvatinib is a multi-kinase inhibitor used to treat thyroid cancer.
  • Limited research exists on lenvatinib's toxicity during vertebrate embryonic development.

Purpose of the Study:

  • To investigate the effects of lenvatinib on early embryonic development in zebrafish.
  • To explore the underlying mechanisms of lenvatinib-induced hepatotoxicity.

Main Methods:

  • Zebrafish embryos were exposed to varying concentrations of lenvatinib.
  • Developmental parameters, liver morphology, gene expression, oxidative stress, and Wnt signaling were analyzed.
  • Intervention with astaxanthin and Wnt signaling activators was performed.

Main Results:

  • Lenvatinib exposure led to abnormal embryonic development, including cardiac issues, edema, and delayed yolk absorption.
  • Hepatotoxicity was observed, characterized by reduced liver area, impaired hepatocyte proliferation, altered metabolism, and abnormal tissue structure.
  • Lenvatinib induced oxidative stress and down-regulated Wnt signaling pathways.
  • Astaxanthin and Wnt pathway activation partially ameliorated lenvatinib-induced hepatic defects.

Conclusions:

  • Lenvatinib induces hepatotoxicity in zebrafish embryos potentially through oxidative stress and Wnt signaling inhibition.
  • Findings highlight potential risks of lenvatinib exposure to embryonic development and fetal health.

Related Concept Videos